Literature DB >> 26175308

Functional outcomes in Rett syndrome.

Frank S Pidcock1, Cynthia Salorio2, Genila Bibat3, Jennifer Swain3, Jocelyn Scheller3, Wendy Shore2, SakkuBai Naidu4.   

Abstract

AIM: To relate functional outcomes to mutation type and age at evaluation in patients with Rett syndrome (RTT).
METHOD: We identified 96 RTT patients with mutations in the MECP2 (methyl-CpG-binding protein 2) gene. Chart analysis, clinical evaluation, and functional measures were completed.
RESULTS: Among 11 mutation groups, a statistically significant group effect of mutation type was observed for self-care, upper extremity function, and mobility, on standardized measures administered by occupational and physical therapists. Patients with R133C and uncommon mutations tended to perform best on upper extremity and self-care items, whereas patients with R133C, R306C and R294X had the highest scores on the mobility items. The worst performers on upper extremity and self-care items were patients with large deletions, R255X, R168X, and T158M mutations. The lowest scores for mobility were found in patients with T158M, R255X, R168X, and R270X mutations. On categorical variables as reported by parents at the time of initial evaluation, patients with R133C and R294X were most likely to have hand use, those with R133C, R294X, R306C and small deletions were most likely to be ambulatory, and those with R133C were most likely to be verbal.
INTERPRETATION: Functional performance in RTT patients may relate to the type of mutation. Knowledge of these relationships is useful for developing appropriate rehabilitation strategies and prognosis.
Copyright © 2015 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Function; Mutation groups; Rett syndrome

Mesh:

Substances:

Year:  2015        PMID: 26175308      PMCID: PMC4695286          DOI: 10.1016/j.braindev.2015.06.005

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  19 in total

1.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

2.  Describing the phenotype in Rett syndrome using a population database.

Authors:  L Colvin; S Fyfe; S Leonard; T Schiavello; C Ellaway; N De Klerk; J Christodoulou; M Msall; H Leonard
Journal:  Arch Dis Child       Date:  2003-01       Impact factor: 3.791

3.  MeCP2 mutations in children with and without the phenotype of Rett syndrome.

Authors:  K Hoffbuhr; J M Devaney; B LaFleur; N Sirianni; C Scacheri; J Giron; J Schuette; J Innis; M Marino; M Philippart; V Narayanan; R Umansky; D Kronn; E P Hoffman; S Naidu
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

4.  Rett syndrome in Spain: mutation analysis and clinical correlations.

Authors:  E Monrós; J Armstrong; E Aibar; P Poo; I Canós; M Pineda
Journal:  Brain Dev       Date:  2001-12       Impact factor: 1.961

Review 5.  Rett syndrome: methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations.

Authors:  R E Amir; H Y Zoghbi
Journal:  Am J Med Genet       Date:  2000

6.  Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients.

Authors:  P Huppke; F Laccone; N Krämer; W Engel; F Hanefeld
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

7.  Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location.

Authors:  J P Cheadle; H Gill; N Fleming; J Maynard; A Kerr; H Leonard; M Krawczak; D N Cooper; S Lynch; N Thomas; H Hughes; M Hulten; D Ravine; J R Sampson; A Clarke
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

Review 8.  Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype.

Authors:  K C Hoffbuhr; L M Moses; M A Jerdonek; S Naidu; E P Hoffman
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2002

Review 9.  Rett syndrome: from the gene to the disease.

Authors:  Tanja Matijevic; Jelena Knezevic; Marko Slavica; Jasminka Pavelic
Journal:  Eur Neurol       Date:  2008-10-24       Impact factor: 1.710

10.  Comparison of Genomic and Epigenomic Expression in Monozygotic Twins Discordant for Rett Syndrome.

Authors:  Kunio Miyake; Chunshu Yang; Yohei Minakuchi; Kenta Ohori; Masaki Soutome; Takae Hirasawa; Yasuhiro Kazuki; Noboru Adachi; Seiko Suzuki; Masayuki Itoh; Yu-Ichi Goto; Tomoko Andoh; Hiroshi Kurosawa; Mitsuo Oshimura; Masayuki Sasaki; Atsushi Toyoda; Takeo Kubota
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

View more
  3 in total

1.  Diagnostic value of partial exome sequencing in developmental disorders.

Authors:  Laura Gieldon; Luisa Mackenroth; Anne-Karin Kahlert; Johannes R Lemke; Joseph Porrmann; Jens Schallner; Maja von der Hagen; Susanne Markus; Sabine Weidensee; Barbara Novotna; Charlotte Soerensen; Barbara Klink; Johannes Wagner; Andreas Tzschach; Arne Jahn; Franziska Kuhlee; Karl Hackmann; Evelin Schrock; Nataliya Di Donato; Andreas Rump
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

2.  Sensory Integration and Functional Reaching in Children With Rett Syndrome/Rett-Related Disorders.

Authors:  Wendy Drobnyk; Karen Rocco; Sara Davidson; Susan Bruce; Fang Zhang; Stephen B Soumerai
Journal:  Clin Med Insights Pediatr       Date:  2019-08-26

Review 3.  A framework for the investigation of rare genetic disorders in neuropsychiatry.

Authors:  Stephan J Sanders; Mustafa Sahin; Joseph Hostyk; Audrey Thurm; Sebastien Jacquemont; Paul Avillach; Elise Douard; Christa L Martin; Meera E Modi; Andres Moreno-De-Luca; Armin Raznahan; Alan Anticevic; Ricardo Dolmetsch; Guoping Feng; Daniel H Geschwind; David C Glahn; David B Goldstein; David H Ledbetter; Jennifer G Mulle; Sergiu P Pasca; Rodney Samaco; Jonathan Sebat; Anne Pariser; Thomas Lehner; Raquel E Gur; Carrie E Bearden
Journal:  Nat Med       Date:  2019-09-23       Impact factor: 53.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.